Infectious disease billing
Infectious disease is a mostly cognitive specialty with two payment structures that belong to no other. In the home, the unit of payment is not a week of therapy or a course of treatment but a calendar day on which a skilled professional was present -- and whether a given antibiotic can be delivered under that benefit at all turns on the equipment it runs through. In the hospital, antimicrobials are the only product class with their own way into the new-technology add-on payment.
- The home infusion payment unit is a day a skilled professional furnished services in the home
- A home infusion drug is defined by delivery through a durable medical equipment pump
- The benefit's definition of home excludes a hospital, critical access hospital or skilled nursing facility
- Antimicrobials have an alternative eligibility pathway into the inpatient new-technology add-on payment
This is an educational guide to how billing works for infectious disease — its workflow, coding, and payer considerations. It is general information, not a statement that US Medical Billing serves this specialty, and not billing, coding, or legal advice.
What makes infectious disease billing distinct
The specialty's characteristic service is a long course of parenteral therapy given outside the hospital, and Medicare's rules for it are built around two definitions that have nothing to do with infection. The first is the payment unit. 42 CFR 414.1550 provides that a unit of single payment is made per payment category for each infusion drug administration calendar day, and 42 CFR 486.505 defines that day as the day on which home infusion therapy services are furnished by skilled professionals in the individual's home on the day of infusion drug administration -- adding that the skilled services provided on such a day must be so inherently complex that they can only be safely and effectively performed by, or under the supervision of, professional or technical personnel. A six-week course in which a nurse visits weekly and the patient runs the pump in between is six payable days inside a forty-two-day course.
The second definition decides whether the benefit applies at all, and it is about hardware. A home infusion drug means a parenteral drug or biological administered intravenously, or subcutaneously over an administration period of fifteen minutes or more, in the individual's home through a pump that is an item of durable medical equipment -- excluding insulin pump systems and drugs on a self-administered drug exclusion list. The payment categories then key themselves to the durable medical equipment local coverage determination for external infusion pumps. So whether a particular antimicrobial can be given at home under this benefit is answered by a coverage determination about pumps, not by a judgment about the infection, and two clinically interchangeable agents can sit on opposite sides of that line.
Site of care is therefore something the rules choose rather than something the clinician does. The same regulation defines home as a place of residence used as the home of an individual, including an institution used as a home -- and then excludes a hospital, a critical access hospital and a skilled nursing facility from that definition. A patient whose antibiotic falls outside the pump definition, or who is in a facility that does not count as a home, receives the same therapy through a different benefit, billed by a different entity, with different cost-sharing. Discharge planning for a course of parenteral therapy is a benefits question before it is a logistics one.
The supplier side is unusually gated. Payment requires the services to be furnished by, or under arrangements with, a qualified home infusion therapy supplier that meets health and safety standards, is accredited by an organization designated by the Secretary, and is separately enrolled in Medicare under its own provision. The regulation also builds in a first-visit differential: the payment amount is set higher for the first visit initiating services in the home and lower for subsequent visits, and where a patient has had home infusion therapy before, the earlier claim must show a discharge and a gap before a first-visit amount may be claimed again.
The inpatient side carries the other structure that belongs only here. The new-technology add-on payment normally requires a technology to represent a substantial clinical improvement over what was previously available. 42 CFR 412.87(d) sets out an alternative pathway for certain antimicrobial products, under which a product designated by the FDA as a Qualified Infectious Disease Product, or approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, qualifies without that showing. The same section allows an antimicrobial applying through that pathway to be conditionally approved for the add-on payment before it has FDA marketing authorization, which no other technology may be. It is the only disease category written into the inpatient prospective payment system's new-technology rules by name.
How infectious disease billing flows
The revenue cycle for a course of parenteral therapy is decided at discharge planning, weeks before the first claim.
Deciding the site of care against the benefit
Whether the therapy can be delivered at home under the home infusion benefit depends on the drug's delivery mechanism and on whether the residence meets the regulation's definition of home. Both are answered before the plan is made, not after the patient is discharged.
Common operational challenges
The recurring difficulty is that clinical equivalence and payment equivalence come apart, repeatedly and in both directions.
Two agents, two benefits
Antimicrobials that are interchangeable at the bedside can fall on opposite sides of the pump definition, so one is deliverable at home under this benefit and the other is not. The choice of agent becomes a site-of-care decision without anyone framing it that way.
A course that is longer than what is payable
A multi-week course generates payment only on the days a professional was present. Forecasting revenue from the length of therapy rather than from the visit schedule overstates it substantially.
A residence that is not a home
The benefit's definition of home excludes a hospital, critical access hospital and skilled nursing facility. A patient discharged to a facility for the convenience of the infusion is often discharged out of this benefit at the same time.
Cognitive work with little procedural revenue
Much of the specialty's value is consultation, stewardship and oversight rather than procedures. That makes evaluation and management documentation, and the separation of the physician's claim from the supplier's, the whole of the professional revenue cycle.
Documentation and coding considerations
The notes below describe payment and coverage rules from the Medicare regulations; they do not reproduce any code descriptions.
The payment unit, as defined
42 CFR 414.1550(b) makes a unit of single payment per payment category for each infusion drug administration calendar day. 42 CFR 486.505 defines that as the day on which home infusion therapy services are furnished by skilled professionals in the individual's home on a day of infusion drug administration, with the skilled services being so inherently complex that only professional or technical personnel can safely and effectively perform or supervise them.
What makes a drug a home infusion drug
A parenteral drug or biological administered intravenously, or subcutaneously over an administration period of fifteen minutes or more, in the individual's home through a pump that is an item of durable medical equipment -- excluding insulin pump systems and drugs on a self-administered drug exclusion list.
Where the payment categories come from
The regulation's categories were built from equivalent office infusion services, and the first category is described as including intravenous infusion drugs for therapy, prophylaxis or diagnosis, with additions tracking the durable medical equipment local coverage determination for external infusion pumps. The pump policy therefore governs the boundary of this benefit.
The plan of care and its signature
Orders must specify the frequency at which services will be furnished and the discipline furnishing them, and may state a range of visit frequency. The plan of care must be signed and dated by the ordering physician before a claim for payment is submitted, and signed again on any change to it.
The antimicrobial pathway in the inpatient rules
42 CFR 412.87(d) provides an alternative eligibility pathway for products designated as Qualified Infectious Disease Products or approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, without the substantial-improvement showing other technologies must make -- and §412.87(f)(3) allows a product applying under it to be conditionally approved before FDA marketing authorization.
Denial and rejection risks
The first two are not really denials; they are claims for services the benefit never covered.
Days billed with no professional present
A day on which the drug was administered but no skilled professional furnished services in the home is not an infusion drug administration calendar day. Billing the course by its length rather than by its visits claims days that were never payable.
A drug outside the pump definition
An agent not administered through a durable medical equipment pump, or one on the self-administered exclusion list, is not a home infusion drug. The claim fails on the definition rather than on necessity, so clinical documentation does not answer it.
Services furnished somewhere that is not a home
The regulation's definition of home excludes a hospital, critical access hospital and skilled nursing facility, so services furnished there fall outside this benefit and belong to whichever payment system covers that setting.
A first-visit amount claimed on a return
Where a patient has previously received home infusion therapy services, the earlier claim must show a discharge and the required gap before a first-visit amount may be claimed. Without it, the higher amount is not supported.
A supplier that does not meet the conditions
Payment requires a qualified supplier meeting the health and safety standards, accredited by a designated organization, and enrolled under the applicable provision. A gap in any of the three invalidates otherwise correct claims for the period it covers.
Payer-process considerations
The federal structure here is unusually prescriptive, and commercial arrangements often are not.
A durable medical equipment policy setting a drug benefit
Because the payment categories track the external infusion pump coverage determination, the operative document for deciding whether a course can be delivered at home is a policy about equipment. It is checked per agent, not assumed from the therapy.
Three separate claims for one course
The infusion services, the drug itself and the physician's professional work reach Medicare through different payment mechanisms and different billers. Reconciling a course of therapy means joining claims that were never on the same form.
Accreditation and enrollment as conditions of payment
The supplier requirements are written into the payment regulation rather than left to contracting, so lapses are payment failures rather than contractual ones and are worth monitoring on the same cadence as credentialing.
Commercial and Medicare Advantage structures differ
Commercial plans and Medicare Advantage plans frequently pay home infusion per diem or per therapy under network arrangements that do not reproduce the calendar-day construction, and may cover agents the federal definition excludes. The same course can be economical under one plan and not another.
Revenue-cycle checkpoints
The first three all happen at discharge planning, which is where this specialty's revenue is decided.
- Confirm the agent is administered through a durable medical equipment pump before planning a home course
- Confirm the residence meets the benefit's definition of home, which excludes a hospital, critical access hospital and skilled nursing facility
- Check the agent against the external infusion pump coverage determination rather than against the therapy generally
- Confirm the supplier meets the health and safety standards, is accredited and is enrolled, for the whole period being billed
- Bill each calendar day on which a skilled professional furnished services in the home, and no others
- Support a first-visit amount with a prior discharge and the required gap where the patient has had these services before
- Keep the physician's evaluation, management and oversight claims separate from the supplier's per-day claims
- Forecast revenue from the visit schedule rather than from the length of the course
Related & connected
Services, tools, background reading and definitions that connect to the infectious disease revenue-cycle steps above.
Related services
- Coding supportSeparating the physician's professional claim from the infusion services and the drug.
- Claims managementFollowing one course of therapy across three payment mechanisms and three billers.
- Denial managementAnswering a definitional denial about the benefit rather than a clinical one about the infection.
Calculators & tools
- Place of service code lookupThe setting codes behind a benefit whose boundary is drawn by where the patient is.
- HCPCS code lookupThe Level II code set that carries drugs, biologicals and the equipment they run through.
- Prior authorization request checklistAssembling the clinical evidence for an authorization that describes a course rather than a visit.
From the Knowledge Base
- Place of service on professional claimsWhy the setting is a claim fact -- and here, a fact that decides which benefit applies at all.
- Medicare Part B drugs and biologicalsHow drugs are covered and priced under Part B, alongside the services that deliver them.
- Place of service denialWhat arrives when the setting on the claim and the benefit being billed do not agree.
- Medicare Part A billingThe institutional side a course of therapy moves into when the home benefit does not reach it.
Glossary
- Place of serviceThe setting code behind a benefit whose own definition of home excludes three facility types.
- HCPCS Level IIThe code set carrying the drugs and the equipment the benefit's definition turns on.
- MS-DRGThe inpatient payment group the antimicrobial add-on pathway pays on top of.
- Covered serviceThe category an antimicrobial enters or misses according to how it is delivered.
Frequently asked questions
What exactly does Medicare pay for under the home infusion therapy services benefit?
A day, not a course and not a drug. 42 CFR 414.1550(b) makes a unit of single payment per payment category for each infusion drug administration calendar day, and 42 CFR 486.505 defines that as the day on which home infusion therapy services are furnished by skilled professionals in the individual's home on the day of infusion drug administration -- with the skilled services being so inherently complex that they can only be safely and effectively performed by, or under the supervision of, professional or technical personnel. Days on which the pump ran without a professional present are part of the therapy and not part of the payment.
Why can some antibiotics be given at home under this benefit and others cannot?
Because the benefit is defined by delivery mechanism. A home infusion drug is a parenteral drug or biological administered intravenously, or subcutaneously over an administration period of fifteen minutes or more, in the individual's home through a pump that is an item of durable medical equipment, and the definition excludes insulin pump systems and drugs on a self-administered drug exclusion list. The payment categories then follow the durable medical equipment local coverage determination for external infusion pumps. Two agents that are clinically interchangeable can therefore sit on opposite sides of the boundary, and the operative document is a policy about pumps.
Does a patient in a skilled nursing facility fall under this benefit?
No. The regulation defines home as a place of residence used as the home of an individual, including an institution that is used as a home -- and then states that such an institution may not be a hospital, a critical access hospital or a skilled nursing facility. Therapy furnished in those settings is covered, where it is covered, through the payment system that applies to them, billed by that provider. That is why a decision to discharge a patient to a facility for the convenience of an infusion is also a decision about which benefit pays for it.
What has to be true of the supplier?
Three things, all conditions of payment. Under 42 CFR 414.1505 the services must be furnished by, or under arrangements with, a qualified home infusion therapy supplier that meets the health and safety standards for such suppliers, meets the requirements in the payment subpart, and is enrolled in Medicare consistent with the applicable enrollment provision. The definition of a qualified supplier also requires the ability to provide and administer home infusion therapy safely on a continuous basis and accreditation by an organization designated by the Secretary.
Is there anything in the inpatient rules specific to infectious disease?
Yes, and it is the only disease category named in them. The new-technology add-on payment normally requires a technology to represent an advance that substantially improves the diagnosis or treatment of Medicare beneficiaries. 42 CFR 412.87(d) creates an alternative pathway for certain antimicrobial products -- a product designated by the FDA as a Qualified Infectious Disease Product with marketing authorization for that indication, or a product approved under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs and used for the approved indication -- which does not require that showing. The regulation also allows a product applying under this pathway to be conditionally approved for the add-on payment for a fiscal year before FDA marketing authorization, which is not available to technologies applying by any other route.
Sources
Last reviewed August 1, 2026.
- Office of the Federal Register / eCFR42 CFR 486.505 Definitions -- the definitions of home infusion drug (a parenteral drug administered through a pump that is durable medical equipment, excluding insulin pump systems and self-administered drugs), infusion drug administration calendar day (a day skilled professionals furnish services in the individual's home), home (excluding a hospital, critical access hospital or skilled nursing facility), and qualified home infusion therapy supplier
- Office of the Federal Register / eCFR42 CFR 414.1550 Basis of payment -- the unit of single payment per payment category for each infusion drug administration calendar day, the three payment categories and their derivation from equivalent office infusion services and the DME local coverage determination for external infusion pumps, and the higher first-visit amount with its prior-discharge and gap conditions. See also 42 CFR 414.1505 (requirement for payment) and 414.1515 (plan of care and signature requirements)
- Office of the Federal Register / eCFR42 CFR 412.87 Additional payment for new medical services and technologies -- paragraph (b) requiring a substantial improvement in diagnosis or treatment, paragraph (d) establishing the alternative eligibility pathway for products designated as Qualified Infectious Disease Products or approved under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs, and paragraph (f)(3) permitting conditional approval for a product applying under that pathway before FDA marketing authorization
Ready to improve your revenue cycle?
Tell us about your practice and we’ll tell you where we would start.